IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast ...

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early ...

Alectinib showed a 22% reduction in death risk compared to crizotinib in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. Significant OS benefits were observed in ...

“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...

Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...

Durvalumab addition to BCG therapy significantly improved DFS in BCG-naive, high-risk NMIBC patients, achieving a 32% reduction in DFS event risk. The combination therapy was well-tolerated, with ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia/death rates with a 50 mg/m2 biweekly docetaxel regimen. Despite a higher cumulative docetaxel dose ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Anbenitamab combined with chemotherapy significantly improved PFS and OS in HER2-positive gastric or GEJ cancer patients compared to chemotherapy alone. The trial showed a 75% reduction in progression ...

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.